Manage stand orders
Select Option

Innokas Medical Ltd.

Vihikari 10, 90440 Kempele
Finland

Contact

Antti Virtanen

Head of Sales

Elina Ihme

Head of Marketing & Communications

Our range of products

Product categories

Our products

Product category: Other medical services and publications

Medical Device Design and Development Services

Since 1994 we have specialized in medical technology services. Throughout these years our service offering has covered all the aspects of medical device product development, from the early product idea enrichment phase through device development and project implementation to transfer to production, and has always been tailored to meet our customers’ specific requirements. 

Our highly skilled engineering team includes all the necessary competences of product development, such as electrical and mechanical engineering, software development, industrial and usability design, prototyping, verification and validation as well as quality, risk and project management.

You have an idea of a Medical Device? Let’s realize it together! Continue reading on Innokas Medical's Website to learn more about our medical device design and development services (link below). 

More Less

Product category: Other medical services and publications

Medical Device Manufacturing Services

Since 1994 we have specialized in medical technology services. Through our 25 years of experience in the MedTech field we’ve gathered extensive knowledge in medical and IVD device manufacturing in our ISO 13485 compliant and FDA registered facilities.

Our manufacturing operations service offering covers all the phases of medical and IVD device manufacturing, from design transfer and production process validation to manufacturing – that is been carried out according to ISO 13485, GMP, CE, Health Canada and FDA requirements – and to the product life cycle management activities that regulations require.

Our three production plants allow us to provide our customers flexible production capabilities and manufacturing volumes, ranging from few systems per year to thousands of units per month, so we are able to operate perfectly according to our customers’ market demand. Our production lines are always tailored specifically according to our customers’ needs.
 
Innokas manufacturing process has ISO 13485:2016 and MDSAP certifications and it also complies with FDA regulations. Our manufacturing process has been fine-tuned especially for medical and in vitro diagnostic devices and high level assembly production, comprising devices from hand-held to table-top units and even to complex diagnostic systems.

Continue reading on Innokas Medical's Website to learn more about our medical device manufacturing services (link below)!

More Less

Product category: Other medical services and publications

Quality and Regulatory Services

To ensure the safety and effectiveness of medical devices as well as to guarantee smooth market entry, the regulations and standards have to be complied throughout the device entire life cycle. This requires holistic understanding of the requirements from relevant regulations and standards. An effective and purpose-built Quality Management System is the means to implement those requirements in practice.

We provide our customers clear and concrete advice that enables them to establish an efficient medical device regulatory roadmap. We also create and establish practical and efficient Quality Management System. The concrete benefits are:
  • Reduced costs thanks to shorter time-to-market, decreased number of iterations during market approval and focus on key process areas
  • Competitive edge thanks to shorter time for market entries, solid baseline for introducing new market areas, solid baseline for implementing design changes and new technologies
  • Peace-of-mind thanks to being sure that your medical device is safe and effective, full readiness to an unannounced audit, risks being under control and mitigated
Thus, by co-creating with Innokas, our customers can ensure that all the quality, regulatory and domain specific requirements are met during each product life cycle phase. Early involvement of our Design Studio, Manufacturing Operations and QA&RA teams ensures that the right things are being done at the right time and in the right order.

Continue reading on Innokas Medical's Website to learn more about our quality and regulatory services (link below)!

More Less

Product category: Other medical services and publications

Medical Software and Data-Driven Healthcare Solutions Development Services

Through our +25 years of experience, we help our customers to develop their software as part of medical device, software as a medical device and data-driven healthcare solution – while taking all relevant requirements and the regulatory framework into account.

Digitalization is revolutionizing the future of healthcare. Both data-driven solutions and SW are playing an increasingly important role in this enabling novel ways to deliver healthcare. On the other hand, more stringent requirements to medical SW, including MDR with new classification rules for SW, are almost here. Companies will have to re-define their practices and processes to comply with the regulations, which is not an optional thing to do.

At Innokas Medical, Quality Driven Medical SW and Co-Creation are the cornerstones in helping you to bring your regulated medical SW and data-driven solution to the market.

“Co-Creation” of “Medical SW” covers your Software as part of Medical Device (Embedded SW), Software as a Medical Device (SaMD), or Data-Driven Healthcare solutions. “Quality Driven” signifies that the specific requirements and the regulatory framework are identified early on and the conformance is built effectively along the development life-cycle.

You have an idea of a Medical SW or Application? Let’s realize it together! Continue reading on Innokas Medical's Website to learn more about our scalable service center model and service offering (link below).

More Less

Company news

Date

Topic

Download

Oct 22, 2020

Innokas Medical is trusted by innovative healthtech brands - what our Clients say?

In addition to being a strategic partner with many leading global medtech brands, Innokas works also with growth companies as well as with new, smaller ones in helping them to enter the market and to grow into successful companies. Please read what our Clients say at: https://www.innokasmedical.fi/references/

More Less

Oct 5, 2020

Innokas Medical develops data-driven solutions and software for regulated medical devices together with its customers

Healthcare technology is one of the largest high-tech export segments of Finnish industry, and it continues to grow strongly year after year. In addition to growth, the industry is evolving with various global trends. One of these is digitalization, which is revolutionizing the future of healthcare.

Health- and patient care can be seen as increasingly complex operative environment. Both aging population and rising life expectancy bring a wide range of challenges for future healthcare. There is huge demand for creation of novel, preventive patient care solutions in the future.

“I believe that digitalization, evolving technologies as well as software will bring new kinds of possibilities for preventive patient care solutions in the future”, ponders Pauli Innamaa, Head of Digital Healthcare Solutions at Innokas Medical’s Design Studio.

In recent years, the trend has been clear: software and data-driven solutions are expected to revolutionize the future of patient care. Software contributes extensively to better functionalities and features of physical medical devices, and for providing reliable and secure connections and communication between devices – as well as to and from the cloud. Additionally, software and artificial intelligence (AI) solutions are able to collect, analyze and visualize large amounts of data – either in the device itself or in the cloud. With new solutions, significant cost savings can be achieved e.g. through preventive care. Additionally, the support to make better health related decision-making can be offered.

“Data analytics and machine learning will have a huge impact on how diseases are prevented, and how patients are treated more personally in the future. It’s clear that we’re talking about an extremely interesting area, in which we at Innokas Medical definitely want to be involved in”, Innamaa continues.

It is estimated that the annual growth rate of digital healthcare market is 28 % worldwide. This is exceptionally high growth rate for any business. Both data-driven solutions and SW are playing an increasingly important role in this and enabling novel ways to deliver healthcare.

Considerable expertise is required for developing regulated medical SW and data-driven solutions
 
Due to digitalization, companies need to be able to develop even more complex and easy-to-maintain and -test software and data-driven solutions. They must meet the growing regulatory requirements and customers’ needs as well. To comply with the regulations is not an optional thing to do.

“Regulated medical software development differs substantially from software developed for, e.g., consumer electronics. In medical device industry, software must meet all regulatory requirements set by the authorities to get the permission to put the product on the market. These requirements evolve all the time to ensure both safety and effectiveness of new technologies and solutions”, Innamaa tells.

Keeping up with the global competition requires continuous development and investments from companies. Keeping this in mind, Innokas Medical’s Design Studio has continuously reinforced its in-house digital healthcare solutions know-how. The existing trends and customers’ needs are being taken into account in both development work and recruitments. One of the latest new talents at Innokas is Antti Kaltiainen (M.Sc., Technology and Information Technology), who started as CTO at Innokas in this autumn .

“I’m working in our Design Studio's Digital Healthcare Solutions function. As company’s new CTO, I’m further developing our competencies to enable us to co-create medical SW and data-driven healthcare solutions for our customers also in the future”, tells Kaltiainen.

Thanks to his strong background within medical device development and IoT – as well as digitalization as a trend revolutionizing the business – he sees his new role at Innokas fascinating. However, the pace of development in medical device industry is in a slight delay when comparing in many other industries. This is caused by more complex regulative scrutiny in the industry; new technologies must achieve a certain level of maturity before they can be approved and adapted for use in medical devices.

“Processing and using the data collected from various devices and sensors will have an enormous potential to improve the cost-effectiveness of healthcare. However, while solutions based on software and algorithms improve, e.g., the cost-effectiveness, a whole new range of risks and safety requirements are emerging. This may slow down the speed of digital revolution”, Kaltiainen ponders and continues:

“However, I believe that the various forms of digitalization are taking over the industry faster than we expect. With next generation solutions, we’re able to streamline the daily work of healthcare professionals and, of course, to create new kinds of business opportunities to our customers. At its best, we’ll also be able to prevent onset of diseases and improve peoples’ lives. Thus, I see the changes taking place in our industry will create significant business opportunities for all of us.”

In addition to healthcare technology, software has also taken over other industries. That's why software experts are in a high demand. However, Jenni Tuulos, working as Head of Design Studio at Innokas Medical, sees that the medical device industry attracts SW developers.

”Even when there is a high demand for software experts in recruitment markets, healthcare technology attracts both experienced professionals and recently graduated talents”, Tuulos ponders and continues:

“Medical device software and data-driven solutions development projects feature very interesting and challenging assignments, which surely have an impact. Additionally, we’re working with meaningful agenda; when we’re developing software for the medical device and solution industry, it aims at preventing, diagnosing and treating patients' illnesses - and thereby improving the quality of peoples’ lives.”

Better outcome by co-creation

While software and digitalization enable the co-creation of next generation digital solutions, it brings a whole new range of challenges for companies working in the field – and for those, as well, who are aiming to enter the field. One of the challenges is the strict and compelling regulations governing healthcare technology. The aim is to ensure the safety and effectiveness of the devices.

”As an example, the new MDR will introduce a new classification rule for software and it must be considered when applying the definition to general medical devices. This means that most software as a medical device (SaMD) will be up-classified as Class II medical device in the new Medical Device Regulation in Europe. Earlier, most of the medical device software was classified into Class I in Medical Device Directive and in IVD directive. This is, of course, only one example – but at the same time, very important one”, Innamaa tells.

“Another interesting area related to this is the utilization of artificial intelligence in medical software; how to deal with the changes in the algorithm caused by machine learning, as the parameters of the algorithm may be updated as new data is processed? Regulations are surely not yet well established in the field”, he continues.

In addition to launching new business function (”Digital Healthcare Solutions”), Innokas has also updated its service offering to meet the changes and challenges in the field. Quality driven medical software and co-creation mindsets as well as associated practices are company’s cornerstones in helping customers to bring their regulated medical SW and data-driven solution to the market effectively and efficiently.

“We are a full-service provider in all areas of medical software and data-driven solutions design and development. Together with our talented partner- and subcontractor network, we’re able to complete our customers’ know-how by extending their R&D and QA&RA competences with our scalable service center model. We’re able to deliver the SW as a service, or resource their on-site team with our experts”, Innamaa explains.

 “Quality Driven” signifies that the specific requirements and the regulatory framework are identified early on and the conformance is built effectively along the development life cycle. Requirements and the regulatory framework are applied in Software as part of Medical Device (Embedded SW), Software as a Medical Device (SaMD) and Data-Driven Healthcare solutions as well. Through the company’s +25 years of experience, Innokas can help its customers to succeed with all QA&RA matters as well.

“These novel ways we’re co-creating with our customers are needed to help people to stay healthy longer and to make better health and healthcare related decisions. We feel it is a privilege to be a part of such a mission for an industry”, concludes Innamaa.

For more information about Innokas’ Medical SW and Data-Driven Solution development services, please go to:
https://www.innokasmedical.fi/quality-driven-medical-software-design-development-services/

More information about the topic:
Pauli Innamaa | Head of Digital Healthcare Solutions, Innokas Medical Ltd. | pauli.innamaa@innokasmedical.fi  
Antti Kaltiainen | CTO, Innokas Medical Ltd. | antti.kaltiainen@innokasmedical.fi

More Less

Sep 28, 2020

Innokas Medical develops and manufactures medical devices for global market areas also in future

Through MDSAP (Medical Device Single Audit) certificate, the companies are able to indicate they operate according to ISO 13485:2016 -standard and regulatory requirements set by Australia, Brazil, Canada, Japan and USA.

“At Innokas Medical, everything begins with the quality built into our processes, products and services. All this can be seen through the high-quality daily work at Innokas. When our employees are following Innokas Medical procedures, the requirements are fulfilled throughout the device whole life cycle”, tells Tiina Kotipalo, Head of QA&RA at Innokas Medical.

The realization of all this in practice has been audited at Innokas by many of Innokas’ customers and Certification Bodies during the past year. The latest audit was conducted by SGS Fimko.

”The latest audit lasted 7 days and it was part of the MDSAP -program. During the audit, the Certification Body inspect how Innokas’ functions correspond to ISO 13485 Quality Management System, Medical Device Directive MDD and Medical Device Single Audit Program MDSAP including Canada requirements. The Certification Body audited our all sites in Kempele, Espoo, Helsinki and Tallinn”, Kotipalo explains.

Innokas Medical started to transfer to MDSAP -program in 2019 by necessary quality management system updates. The first audit in MDSAP program was conducted last year, after which Innokas was granted with MDSAP certificate.

“In autumn 2019 the first audit of the MDSAP program was conducted at Innokas, and the most recent one was the first surveillance audit. The next audit will be conducted again next year by SGS Fimko”, Kotipalo tells and continues:

“The auditing program of MDSAP is accurate as auditors inspect companies through a well-defined task-based approach. The result of the audit at Innokas was very good as we got only few minor findings. We've already started to implement the corrective actions. Additionally, we got lot of good feedback from the auditors; our Quality Management System was said to be excellent, personnel competent and the tools, especially on the design and development side, was said to be efficient. Additionally, our manufacturing was found very professional and to be in good control. Thanks for the excellent results like this belong to all Innokas employees!”

In addition to own personnel, Kotipalo would like to thank SGS Fimko as professional Certification Body.

“The suitability of our quality management system was verified with solid expertise by several experienced and trained auditors”, she praises.

By MDSAP certificate companies are able to demonstrate their global capability

The audits conducted in the MDSAP -program are currently required only by Health Canada. However, these audits have also been recognized by several other regulators. This means that through MDSAP certificate, the companies are able to demonstrate organization’s quality management system will satisfy the requirements of the medical device regulatory authorities participating in the MDSAP program. The MDSAP members are at the moment: Therapeutic Goods Administration of Australia, Brazil’s Agência Nacional de Vigilância Sanitária, Health Canada, Japan’s Ministry of Health, Labour and Welfare, and the Japanese Pharmaceuticals and Medical Devices Agency and U.S. Food and Drug Administration.

“As an example, FDA's Centre for Devices and Radiological Health (CDRH), who is responsible for regulating companies who manufacture, repackage, relabel, and import medical devices sold in the US, accept MDSAP audit reports as a substitute for routine Agency inspections”, Kotipalo explains.

At Innokas Medical, the regulatory requirements of Canadian authorities have been built in the company’s processes and practices already earlier as Innokas had CMDCAS 13485 certificate before the MDSAP one. CMDCAS certificate was required from medical device manufacturers and distributors before they were able to sell and market their medical devices in Canada. Now the certificate is been replaced with MDSAP certificate, which was granted for Innokas early this year. Additionally, Innokas has ISO 13485:2016 certificate for design and manufacture of medical devices, and all of the company’s sites have FDA registration as well.

“These certificates are essential for Innokas to be able to convince our customers and regulatory authorities that Innokas is capable to design and manufacture medical devices to the worldwide market”, Kotipalo concludes.

For more information, please contact:
Tiina Kotipalo | Head of QA&RA | Innokas Medical Ltd.: tiina.kotipalo@innokasmedical.fi

More Less

Jun 17, 2020

Fasten your medical device’s way to US market by ensuring you’re familiar with FDA rules and regulations

The design and manufacturing of medical devices is way more challenging than engineering work and factory production of e.g. consumer electronics. In medical device business, it is not enough to have just a good end-product - the development and production processes also have to fulfill certain criteria. The companies must also be able to verify that they operate according to them. The authorities must exercise constant vigilance so that the safety and effectiveness of the device are ensured and verified before companies launch their devices to the market.

The “criteria” includes, e.g., the quality management system (QMS), which is a “must have” for every medical device designer and manufacturer. It covers processes related to the medical device’s development, manufacturing and maintenance throughout its whole life cycle. In addition to QMS, the regulatory requirements concerning medical devices are compelling. The operation of medical device designers and manufacturers is regulated, e.g., by region and country-specific laws and legislation. For example, EU’s medical device directive describes how a designer and manufacturer of medical devices has to operate.

In USA, there are own country-specific laws and legislation, as well. FDA's Centre for Devices and Radiological Health (CDRH) is responsible for regulating companies who manufacture, repackage, relabel, and/or import medical devices sold in the US. These regulations apply to specification developers, contract manufacturers and importers. The aim of the FDA regulations is to protect patients and users and to ensure safety and effectiveness of the devices. FDA regulations are a must for companies heading the US market.

Do you have an idea of a medical device? Or have you already started to develop your medical device? Do you want to enter the US market? If you answered yes, FDA rules and regulations is one very important matter you should be aware of. To fasten your product’s way to US market, you should ensure that your team is familiar with FDA regulations, which are a must for companies heading the US market. Follow this blog post to read our tips for medical device companies for US market entry!

Tip #1. Update your QMS to be compliant with FDA 21 CFR Part 820 (QSR)
 
One very important foundation is that all players in the medical device industry should have a quality management system compliant with FDA 21 CFR Part 820 (QSR) in place. The requirements set in the QSR are similar requirements that ISO 13485 standard has, but they are not identical. Therefore, manufacturers selling to Europe and heading to US markets must update their quality management system according to FDA requirements.

FDA does not require a pre-registration audit, but you’re required to be in compliance with applicable sections of the QSR before placing your device on the market. After that, the FDA conducts pre-announced and random, unannounced inspections to ensure your compliance. This includes inspections at contract manufacturer when the manufacturing has been outsourced.

Tip #2. To get your device classified and regulated by FDA, get yourself familiarized with a risk-based approach that is used
 
The approvals granted by the FDA is a necessary prerequisite to achieving the market authorization for the device. FDA uses risk-based approach when classifying and regulating medical devices.

The device classification regulation defines the regulatory requirements for a general device type. The devices are classified into three classes: Class I, Class II and Class III, and the type of pre-marketing application required for FDA clearance is mainly related to the class in which your device is assigned. Device classification depends on the intended use of the device and also upon indications for use.

The amount of regulatory controls naturally increases from Class I to Class III devices. The regulatory controls are divided in three categories; General controls, Special Controls and Premarket Approval (PMA).

General controls mean regulatory requirements authorized by the FD&C Act, under sections 501, 502, 510, 516, 518, 519, and 520. General controls apply to all medical devices, unless exempted by regulations. With Class I devices, the least regulatory control is applied.

Special controls are usually device-specific for Class II devices. This include, e.g., performance standards, post-market surveillance, patient registries, special labeling requirements, pre-market data requirements and other guidelines.

The devices with the highest risk – Class III – require FDA approval of premarket approval application (PMA) before marketing. To be able to receive approval from FDA for Class III devices, the manufacturer must demonstrate with sufficient, valid scientific evidence that there is a reasonable assurance that the devices are safe and effective for their intended uses.

Tip #3. Remember to follow the device labeling requirements set by FDA

There are several regulations related to medical devices labeling set by FDA. It should be noted that the labeling regulations include instructions for use as well as advertising material. Unique Device Identification is regulated in 21CFR Part 830 and is mandatory in US.

There are also requirements for manufacturing facilities related to labeling. The QA program must be adequate to ensure that labeling meets the GMP device master record requirements with respect to legibility and adhesion, and to ensure that labeling operations are controlled so that correct labeling is always issued and used.

Tip #4. Follow the FDA regulations throughout the whole lifecycle of your medical device
 
The companies should get themselves familiarized with the classifications, regulations and rules of FDA already at the idea phase of the device life cycle, if the aim is to enter the US market. This is because FDA regulations apply both to design and development as well as to manufacturing of the device.

It is crucial is that you have a design team that is familiar with FDA requirements. To fasten your product’s way to US market, you should ensure that your design team, whether in-house or a partner, knows about Design Control requirements FDA has set in FDA 21 CFR Part 820 as well as in other regulations and recognized standards. Design team should be aware of different guidance FDA has given related to device design and development, as well.

There are a number of guidelines written by FDA, that can help designers to prepare documentation that is as such useful when compiling application papers for example for FDA 510(k) submission. To avoid extra costs, double work and unnecessary documentation, choose a team that has robust processes for design control and experience of technical matters as well as regulatory requirements.

If you need a contract manufacturer, be sure that you have a partner that is compliant with FDA QSR and who has registered their establishments in the FDA register. Preferably, your contract manufacturer has a long experience of the FDA compliant QMS over the years and is familiar with the inspection protocols of the FDA. This ensures that the manufacturer has good manufacturing controls such as internal audits, management reviews, production and process controls and CAPA procedures etc. in place. Preferably, your contract manufacturer has also a MDSAP certificate. The Medical Device Single Audit Program allows an MDSAP recognized Auditing Organization to conduct a single regulatory audit of a medical device manufacturer that satisfies the relevant requirements of the regulatory authorities from US, Canada, Australia and Japan. US FDA accepts MDSAP audit reports as a substitute for routine Agency inspections. 

The basic regulatory requirements, that manufacturers of medical devices distributed in the U.S. must comply with, are; Establishment Registration and Medical Device Listing - 21CFR Part 807, Premarket Notification 510(k) - 21 CFR Part 807 Subpart E, Premarket Approval (PMA) - 21 CFR Part 814, Investigational Device Exemption (IDE) - 21CFR Part 812, Quality System Regulation (QS regulation) - 21 CFR Part 820, Labelling - 21 CFR Part 801 and Medical Device Reporting - 21 CFR Part 803.

More Less

Jun 12, 2020

EU funding helps companies to establish valuable international networks

Original source: Business Finland

Innokas Medical, which offers design and development, contract manufacturing as well as quality and regulatory services for medical device OEMs, is one great example of a company that has taken advantage of EU funding opportunities together with its customers. The international consortium that Innokas took part in has brought valuable know-how and helped the company to enter international markets.

Innokas Medical has participated in the Fast Track to Innovation (FTI) -project included in the European Horizon 2020 funding program. FTI is intended to smaller consortium projects, and it aims to accelerate the rapid entry of high-level innovations into international markets. FTI is still relatively underutilized financing model in Finland. However, for Innokas Medical, this financing model and participation in an international consortium is natural part of their operative model, as the company acts as a design and product development as well as contract manufacturing partner for its customers. In addition, Innokas offers a wide range of quality and regulatory services.

“We’ve took part in various consortiums, usually led by our customers", tells Antti Virtanen, Head of Sales at Innokas Medical.

“In the Fast Track to Innovation -project launched in 2016, we developed a home treatment solution for Peripheral Arterial Disease (PAD) together with our Norwegian customer. The product received CE mark in 2018 and today both production and sales have started. Therefore, the project has been successfully completed”, he continues.

The co-creation project brought valuable know-how for Innokas and helped the company to establish new international networks.

“We were able to develop our expertise and know-how even further in managing this kind of projects, which we see very valuable for us. Additionally, it helped us to enter the Norwegian market through the visibility it brought us. Our Norwegian client has also given us a permission to use this project as a public reference, which in our opinion tells us about the successful cooperation”, Virtanen discusses and continues:

“We see it very valuable that through the EU-funded consortiums like this, we’re able to co-create new kinds of innovations with our customers and other cooperation partners to improve peoples’ lives all over the world.”

Applying funding requires effort and skills

Usually, the product development cycle of a medical device is long. Typically it might last even up to 1 to 3 years, requiring long-term financing. On the public side, it can be nationally applied from, e.g., Business Finland, and internationally through, e.g., Horizon 2020 and Eureka programs.

“We see the awareness towards the jungle of rules and regulations, which are mandatory in the medical field, has increased significantly. In addition, it seems that companies have even better understanding on the fact that bringing an innovation to the market requires long-term financing. Before any product brings cashflow for companies, external financing is needed to secure a relatively long transition period from idea to final product”, Virtanen ponders.

However, to apply and receive any funding requires effort and skills. 

"During the past six months we’ve received several cooperation proposals for financial applications. However, only few of all Horizon applications are accepted and funded; behind any good application there must be a knowledgeable and skilled team that can carry out the project by itself. According to our experience, this will significantly improve the chances to get the application accepted and funded”, he tells.

Cooperation contributes to the internationalization and growth of businesses, but also provides an opportunity to be at the forefront of changes in the industry.

”Co-creation projects like this help both us and our customers to develop and carry out larger product development projects, which improves the patient and health care globally”, Virtanen discusses.

Innokas Medical is also involved in facilitating the changes in the industry by actively participating in international regulatory work.

“Healthcare technology is increasingly attracting new players from outside the industry, like from software side. These companies need an understanding of the requirements of the medical device industry in order to gain market acceptance for their products. We know the regulatory environment and we can implement the requirements in practice. We can also help our customers to develop and manufacture products as specified, helping them to succeed in entering markets with their innovations”, he concludes.

For more information about Fast Track to Innovation -funding:
Heini Günther, Business Finland, heini.gunther@businessfinland.fi / 040 502 0042

For more information about Innokas Medical:
Antti Virtanen, Head of Sales, antti.virtanen@innokasmedical.fi

More Less

About us

Company details

Innokas Medical produces healthcare technology development projects and products to leading international companies and Nordic growth companies and start-ups. We have lived for healthcare technology for over 25 years. Since 1994 we’ve improved the quality of people’s lives by crafting healthtech ideas to reality.

We offer
  • high-quality design and development
  • contract manufacturing, as well as
  • quality and regulatory services
 We’re also improving and completing the future of human centric healthcare by bringing technology, data and security to work together. We focus on implementing solutions for difficult issues, which provide benefit to our customers throughout the whole product life cycle.

We have offices in the Oulu and Helsinki region in Finland, and in Estonia. Innokas Medical is part of Paree Group, a Finnish family-owned company, with a strong focus in international operations and continuous development.

You have an idea of a Medical Device? Let’s realize it together! You may also read more at: www.innokasmedical.fi

More Less

Company data

Sales volume

10-49 Mio US $

Number of employees

100-499

Foundation

1994

Area of business
  • Electromedical equipment / Medical Technology
  • Medical Services and Publications